PMID- 24194642
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20131106
LR  - 20211021
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 9
DP  - 2013
TI  - Combination treatment with risperidone long-acting injection and 
      psychoeducational approaches for preventing relapse in schizophrenia.
PG  - 1655-9
LID - 10.2147/NDT.S52317 [doi]
AB  - A recent meta-analysis showed that long-acting injectable (LAI) antipsychotics 
      were not superior to oral antipsychotics for preventing relapse in patients with 
      schizophrenia. We therefore designed a treatment strategy combining risperidone 
      LAI and COMPASS (COMprehensive Psycho-educational Approach and Scheme Set), an 
      original psychoeducational program supporting treatment with risperidone LAI and 
      evaluating subjective treatment satisfaction, transition of symptoms, and 
      effectiveness in preventing symptomatic relapse. The aim of this study was to 
      examine whether addition of COMPASS to risperidone LAI was more effective in 
      preventing relapse in schizophrenia patients than risperidone LAI alone, with the 
      latter group consisting of patients enrolled in a Phase III trial of risperidone 
      LAI in Japan. Patients were followed up for 6 months, with COMPASS continuously 
      implemented from the transition to the observation phase. The primary efficacy 
      measurements were relapse rate (rates of rehospitalization and discontinuation 
      due to inefficacy). Secondary efficacy measurements were the Brief Psychiatric 
      Rating Scale (BPRS) and Global Assessment of Functioning (GAF) scores. Of the 96 
      patients originally enrolled, 19 (19.8%) were discontinued from all causes. 
      During the 6-month study period, ten of the 96 patients (10.4%) relapsed, 
      compared with a 12.2% relapse rate in patients enrolled in a Phase III trial of 
      risperidone LAI in Japan. Patients showed significant improvements in BPRS total 
      scores (P = 0.0031), BPRS positive (P = 0.0451), BRPS negative (P < 0.0001), and 
      general subscale scores (P = 0.0031), and GAF (P < 0.0001) from baseline to 6 
      months. In conclusion, the lower relapse rate observed in patients treated with 
      COMPASS plus risperidone LAI than in patients treated with risperidone LAI alone 
      suggests that COMPASS may have benefits in the treatment of schizophrenia, 
      indicating a need for randomized, controlled trials in larger numbers of 
      patients.
FAU - Zhao, Yueren
AU  - Zhao Y
AD  - Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, 
      Aichi, Japan ; Department of Psychiatry, Okehazama Hospital Fujita Kokoro Care 
      Center, Toyoake, Aichi, Japan ; Department of Neuropsychiatry, Graduate School of 
      Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan.
FAU - Kishi, Taro
AU  - Kishi T
FAU - Iwata, Nakao
AU  - Iwata N
FAU - Ikeda, Manabu
AU  - Ikeda M
LA  - eng
PT  - Journal Article
DEP - 20131029
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC3814926
OTO - NOTNLM
OT  - adherence
OT  - psychoeducation
OT  - risperidone long-acting injection
OT  - schizophrenia
EDAT- 2013/11/07 06:00
MHDA- 2013/11/07 06:01
PMCR- 2013/10/29
CRDT- 2013/11/07 06:00
PHST- 2013/11/07 06:00 [entrez]
PHST- 2013/11/07 06:00 [pubmed]
PHST- 2013/11/07 06:01 [medline]
PHST- 2013/10/29 00:00 [pmc-release]
AID - ndt-9-1655 [pii]
AID - 10.2147/NDT.S52317 [doi]
PST - ppublish
SO  - Neuropsychiatr Dis Treat. 2013;9:1655-9. doi: 10.2147/NDT.S52317. Epub 2013 Oct 
      29.